MOR 106
MOR106-CL-201
Phase 2 small_molecule terminated
Quick answer
MOR 106 for Atopic Dermatitis is a Phase 2 program (small_molecule) at Lakefront Biotherapeutics NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lakefront Biotherapeutics NV
- Indication
- Atopic Dermatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated